CardieX (ASX:CDX) - Managing Director & CEO, Craig Cooper (left)
Managing Director & CEO, Craig Cooper (left)
Sourced: CardieX
Market Herald logo


Be the first with the news that moves the market
  • Medi-tech company CardieX (CDX) has hit a major milestone in creating wearable blood pressure management tech
  • The company said it was able to extract medical-grade information from consumer-grade technology, called PPG
  • PPG sensors are used widely in wearable devices to detect basic health metrics like heart rate and other fitness indicators
  • However, CardieX says it has found a way to use this tech to collect data normally only available from its clinical SphygmoCor technology
  • Shares in the company are trading 22 per cent higher today, currently worth 2.2 cents each

Medi-tech developer CardieX (CDX) has hit a major milestone in its creation of the next generation of wearable blood pressure management tech.

Through its subsidiary AtCor and joint venture (JV) partner Mobvoi, CardieX has essentially found a way to extract medical-grade patient data from conventional PPG sensor-based wearable devices.

The company has been able to detect a series of heart and arterial health features that can help with the remote diagnosis and monitoring of hypertension and cardiovascular disease.

The information gathered from the tech is comparable to CardieX’s Food and Drug Administration (FDA)-approved “gold standard” SphygmoCor device.

SphygmoCor vs PPG

In order to start to understand the gravity of CardieX’s claims, it’s important to understand the basics behind the company’s SphygmoCor tech and the common PPG tech.

Essentially, SphygmoCor is a medical-grade device used for central arterial pressure waveform analysis. Simply put, the device helps physicians care for patients with severe conditions like hypertension, renal disease, diabetes, heart failure, and more.

According to CardieX, the tech is the industry standard for non-invasive blood pressure waveform assessment.

On the other hand, PPG, or photoplethysmography, sensors use light-based technology to determine the rate of blood flow and the heart’s pumping action.

The way CardieX puts it, PPG sensors are widely used on wearable devices to show “consumer-grade” vital signs like heart rates and other general fitness identifiers.

Smartwatches that help users exercise often make use of PPG tech to give information on basic health metrics.

The two key takeaways are this: PPG tech is easily accessible and provides access to basic medical information, while SphygmoCor is used in clinics for more in-depth analysis.

PPG evolution

Today, CardieX told shareholders it has found a way to extract in-depth data
using PPG sensors that is normally only accessible from the SphygmoCor device.

In human studies made up of 13 subjects between the ages of 20 to 65, AtCor was able to collect specific heart and arterial function data through PPG sensor technology.

CardieX said AtCor was able to determine four unique heart and arterial health features that have never before been extracted from a PPG sensor.

“During the study period, AtCor was able to extract from a PPG sensor substantially equivalent data that is usually only obtained by medical-grade devices such as the company’s SphygmoCor technology,” CardieX told shareholders this morning.

Normally, SphygomoCor data can only be obtained through a blood pressure armband attached to the clinical device.

Today’s breakthrough opens the door for wearable devices to collect in-depth and important data like never before — making personalised health and risk management more effective.

Further, given the PPG sensors leverage the intellectual property from the SphygmoCor device, CardieX said it believes it is well-placed to fast track FDA clearance for the new PPG device.

Shares in CardieX are trading 22.22 per cent higher at lunchtime AEDT today, currently worth 2.2 cents each.

CDX by the numbers
More From The Market Herald
The Market Herald Video

" Emyria (ASX:EMD) launches phase 3 EMD-RX5 trial

Emyria (ASX:EMD) has launched its phase three clinical trial of its ultra-pure CBD candidate.
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials

Prescient Therapeutics (ASX:PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its…
The Market Herald Video

" Opthea (ASX:OPT) secures up to US$260m in funding for OPT-302 trials

Opthea (ASX:OPT) secures up to US$170 million in financing and a US$90 million placement to advance…
Creso Pharma (ASX:CPH) -

" Creso Pharma’s (ASX:CPH) ImpACTIVE appoints new brand ambassador

Creso Pharma's (ASX:CPH) subsidiary, ImpACTIVE has appointed multi-sport performance coach Kolby Tullier as brand ambassador.